Stem cell therapy for human brain disorders  by Lindvall, Olle & Kokaia, Zaal
Kidney International, Vol. 68 (2005), pp. 1937–1939
Stem cell therapy for human brain disorders
OLLE LINDVALL and ZAAL KOKAIA
Laboratory of Neurogenesis and Cell Therapy, Section of Restorative Neurology, Wallenberg Neuroscience Center, University
Hospital, Lund, Sweden; Laboratory of Neural Stem Cell Biology, Section of Restorative Neurology, Stem Cell Institute, University
Hospital, Lund, Sweden; and Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund, Sweden
Stem cell therapy for human brain disorders. Transplantation of
stem cells or their derivatives, and mobilization of endogenous
stem cells in the adult brain, have been proposed as future ther-
apies for various brain disorders such as Parkinson’s disease and
stroke. In support, recent progress shows that neurons suitable
for transplantation can be generated from stem cells in culture,
and that the adult brain produces new neurons from its own
stem cells in response to injury. However, from a clinical per-
spective, the development of stem cell–based therapies for brain
diseases is still at an early stage. Many basic issues remain to be
solved and we need to move forward with caution and avoid
scientifically ill-founded trials in patients. We do not know the
best stem cell source, and research on embryonic stem cells and
stem cells from embryonic or adult brain or from other tissues
should therefore be performed in parallel. We need to under-
stand how to control stem cell proliferation and differentiation
into specific cell types, induce their integration into neural net-
works, and optimize the functional recovery in animal models
closely resembling the human disease. All these scientific ef-
forts are clearly justified because, for the first time, there is now
real hope that we in the future can offer patients with currently
intractable diseases effective cell-based treatments to restore
brain function.
The basic principle of cell therapy is very simple: to
restore brain function that has been lost due to dam-
age or disease by replacing dead cells with new healthy
cells through transplantation. Given the complexity of
human brain structure and function, this prospect may
seem remote. However, if cell replacement will work in
the human brain, it could provide radical new therapies
for severe neurodegenerative disorders like Parkinson’s
disease and stroke. Whether it will work or not will de-
pend on, first, if the grafted neurons can survive and form
connections in the patient’s brain and, second, if the pa-
tient’s brain can integrate and use the grafted neurons.
Available evidence supporting that cell therapy may
work in patients with brain disorders mainly originates
from clinical trials with intrastriatal transplantation of hu-
man embryonic mesencephalic tissue, rich in postmitotic
dopamine neurons, in Parkinson’s disease patients. These
studies demonstrate that grafted dopamine neurons can
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survive, reinnervate the striatum, and restore dopamine
release for up to 10 years despite an ongoing disease pro-
cess, which destroys the Parkinson’s disease patient’s own
dopamine neurons [1, 2]. Several open-label trials have
reported clear clinical benefit [3, 4]. Some patients have
even been able to withdraw L-DOPA treatment for sev-
eral years and resume an independent life [2]. However,
other patients have showed only modest or no improve-
ment after grafting [5, 6], which illustrates that transplan-
tation procedures are far from optimal. Taken together,
the clinical trials with transplantation of embryonic mes-
encephalic tissue in Parkinson’s disease patients provide
proof-of-principle for the cell replacement strategy in the
human brain.
It is unlikely that transplantation of human embry-
onic mesencephalic tissue will become a treatment for
large numbers of Parkinson’s disease patients. Problems
with tissue availability and standardization of the graft
lead to too much variation in functional outcome. The
most important goal for cell therapy research in Parkin-
son’s diease is now to develop strategies to generate large
numbers of functional dopamine neurons in preparations
which are standardized and quality-controlled. The stem
cell technology has the potential to provide solutions to
these technical issues. Results from clinical trials and an-
imal models have identified a set of requirements which
probably have to be fulfilled by the stem cell-derived neu-
rons in order to induce marked clinical improvement after
transplantation: (1) the cells should release dopamine in
a regulated manner, and need to have the molecular, mor-
phologic, and electrophysiologic properties of substantia
nigra dopamine neurons, which should be replaced [7]; (2)
when tested prior to clinical application, the cells must be
able to reverse motor deficits in animal models of Parkin-
son’s disease resembling the symptoms in patients; (3) the
yield of cells should be sufficient to allow for 100,000 or
more grafted dopamine neurons to survive long-term in
each human putamen [8]; (4) The grafted dopamine neu-
rons should reestablish a dense terminal network in most
parts of the denervated striatum; and (5) the grafts have
to become functionally integrated into host basal ganglia-
thalamo-cortical neural circuitries [9].
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Cells with at least some properties of mesencephalic
dopamine neurons have been generated in vitro from
stem cells of four different sources: embryonic stem
cells, neural stem cells in the embryonic and adult brain,
and stem cells in other tissues (e.g., bone marrow) [10].
Currently, the most effective production of dopamine
neurons suitable for transplantation has been reported
from mouse embryonic stem cells [10]. Large numbers
of dopamine neurons can also be generated from human
embryonic stem cells [11], but the survival after trans-
plantation in animals models has been poor. A general
problem with the stem cell–derived neurons described so
far is that it we still do not know to what extent they can
reinnervate the denervated striatum after transplantation
and release dopamine in vivo, and if they can improve be-
havioural deficits resembling Parkinson’s disease motor
symptoms in patients.
It should be emphasized that the availability of virtually
unlimited numbers of dopamine neurons, generated from
stem cells, will not automatically mean that we have a
clinically competitive cell therapy for Parkinson’s disease.
We have to define better selection criteria for patients
with respect to stage and type of disease, and determine
the preoperative degeneration pattern so that we know
what needs to be repaired. The clinical transplantation
procedure should be tailor-made with respect to dose and
location of grafted cells based on preoperative imaging
so that the repair of the dopamine system in striatum
and extrastriatal areas is as complete as possible in each
patient’s brain. The risk for teratoma from embryonic
stem cells, and the consequences of the introduction of
new genes in stem cell–derived neurons should also be
carefully evaluated after transplantation in experimental
animals.
The possibility to restore brain function by transplan-
tation of stem cells or cells predifferentiated in vitro from
stem cells is being explored also in stroke [10]. In addition,
recent findings in rodents have suggested an alternative
approach to cell replacement therapy in this disorder
based on the adult brain’s ability to produce new neu-
rons from its own neural stem cells. Stroke leads to in-
creased generation of neurons from neural stem cells in
the subventricular zone, lining the lateral ventricles [12–
14]. These immature neurons migrate into the damaged
striatum, where they express markers of striatal medium
spiny projection neurons. Thus, the new neurons seem
to differentiate into the phenotype of most neurons de-
stroyed by the ischemic lesion.
Currently, there is a lot of enthusiasm about the ther-
apeutic potential of endogenous neurogenesis in stroke
[15]. However, we still have very little knowledge about
the importance of endogenous neurogenesis for brain
repair, and how the various steps of neurogenesis are
regulated after stroke. Also, we do not yet know if the
new neurons are functional and become integrated into
host neural circuitries. A major scientific challenge is to
develop strategies to promote survival of the new neu-
rons formed after stroke because many of them die.
Several factors can increase adult neurogenesis by stim-
ulating formation and/or improving survival of new
neurons [e.g., fibroblast growth factor-2 (FGF-2), epi-
dermal growth factor (EGF), stem cell factor, ery-
thropoietin (EPO), brain-derived neurotrophic factor
(BDNF), caspase inhibitors, and anti-inflammatory drugs
[16, 17]. Inflammation has been shown to be detrimen-
tal for neurogenesis in the dentate gyrus [18, 19]. Be-
cause stroke causes inflammation, these data suggest that
inflammation-mediated suppression of neurogenesis may
limit the effectiveness of neuroregenerative responses in
this disorder.
Stem cell–based approaches for the first time offer
real hope that we in the future will be able to offer
patients with currently intractable brain disorders effec-
tive treatments. However, we need to know much more
about mechanisms of cell proliferation, differentiation
and survival, and of regeneration and functional recov-
ery. Research on different sources of stem cells and on en-
dogenous neuroregenerative responses should continue
in parallel. It is important to emphasize that the biologic
problems that have to be solved in order to develop safe
and effective stem therapies are complex and should not
be underestimated.
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